Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
US12282014B2 · kind B2 · utility
0Cited by
53References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2016 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | May 6, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/02
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides methods of screening for compounds that interfere with the interaction between ERG. ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.